KIT
Brand: Tandem
Pump name: T:Slim
Sensor augmented: Yes, with G6 CGM
from Dexcom.
Colour display: Yes
Careline:
In August 2018 in the US, Tandem
Diabetes Care launched its insulin pump
with predictive low glucose suspend
feature, having gained FDA approval
for the t:slim X2 pump with Basal-IQ
technology. This pump became available
in the UK earlier this year (2019) and
includes a predictive low glucose suspend
feature designed to reduce the frequency
and duration of hypos. Using the Basal-IQ
algorithm, the system predicts where
a user's blood sugar levels are trending
as far as 30mins into the future. When
the algorithm predicts low glucose
levels, the device suspends insulin
delivery, but automatically resumes once
glucose levels begin to rise. It works with
Dexcom's G6 CGM, which eliminates the
need for blood tests, even for calibration.
Customers using older versions of
Tandem's t:slim X2 could add Basal-IQ
technology via a remote software update.
This ability to provide remote software
updates allows in-warranty t:slim X2 pump
to add updates to their current pumps
using a personal computer. The company
now expects to offer its users an upgrade
to its Control-IQ 'advanced hybrid closedloop technology'. Control-IQ
is designed
to predict glucose levels 30mins ahead
and adjust insulin delivery accordingly,
whether falling or rising. A trial held in
the US this year (2019) found that an
artificial pancreas system from Tandem
Diabetes Care was more effective than
existing treatments for people with Type
1 diabetes.
The Tandem system combines
its t:slim X2 insulin pump and
Control-IQ advanced hybrid
closed-loop technology with
Dexcom's G6 CGM.
Air Liquide Healthcare
READ MORE ABOUT THE T:SLIM ON P.30.
Results from the study were published
in the New England Journal of Medicine.
The trial randomly assigned 168 Type 1
patients ages 14 or older to either the
Tandem device or treatment with the G6
CGM and another insulin pump that did
not automatically adjust insulin. Patients in
the Control-IQ arm increased the amount
airliquidehealthcare.co.uk/tandem
of time in glucose level range (TIR) by an
average of 2.6 hours a day and showed
improvements in time spent with high
and low blood glucose, HbA1c and other
measures compared to the control group
with no severe hypoglycaemia events
reported.